<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Patients receiving <z:hpo ids='HP_0011010'>chronic</z:hpo> transfusion for <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> or <z:e sem="disease" ids="C0019045" disease_type="Disease or Syndrome" abbrv="">hemoglobinopathy</z:e> are believed to be at high risk for developing red blood cell alloantibodies, while those undergoing chemotherapy for <z:hpo ids='HP_0001909'>leukemia</z:hpo> are believed to be at low risk </plain></SENT>
<SENT sid="1" pm="."><plain>To test this hypothesis, we studied the acquisition of new alloantibodies in 703 transfused patients </plain></SENT>
<SENT sid="2" pm="."><plain>While none of 99 patients with lymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> made new antibodies, patients with myelogenous <z:hpo ids='HP_0001909'>leukemia</z:hpo> (16%), <z:e sem="disease" ids="C0019045" disease_type="Disease or Syndrome" abbrv="">hemoglobinopathy</z:e> (29%), <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (11%), <z:hpo ids='HP_0002239'>gastrointestinal bleeding</z:hpo> (11%) or <z:hpo ids='HP_0000083'>renal failure</z:hpo> (14%) made antibodies at statistically similar rates </plain></SENT>
<SENT sid="3" pm="."><plain>Lymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> or its treatment is characterized by a lack of immunologic response to transfusion </plain></SENT>
<SENT sid="4" pm="."><plain>Patients with <z:e sem="disease" ids="C0019045" disease_type="Disease or Syndrome" abbrv="">hemoglobinopathy</z:e> or <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> do not appear at statistically significant greater risk of <z:e sem="disease" ids="C0948201" disease_type="Disease or Syndrome" abbrv="">alloimmunization</z:e> than many other patients requiring <z:hpo ids='HP_0011010'>chronic</z:hpo> transfusion </plain></SENT>
<SENT sid="5" pm="."><plain>Neither intensive chemotherapy for myelogenous <z:hpo ids='HP_0001909'>leukemia</z:hpo> nor the <z:mp ids='MP_0009644'>uremia</z:mp> of <z:hpo ids='HP_0000083'>renal failure</z:hpo> significantly suppress the formation of blood group antibodies </plain></SENT>
</text></document>